Roxee Medication Guide

Trilostane

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Dog Reference complete FDA data linked Rx required Capsule Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Illustration placeholder

Trilostane

Drug type: Generic ingredient • Branded profile • FDA branded products available

Dog Capsule Rx required 100% reference complete

Species: Dog

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Trilostane

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks. Species commonly shown: Dog.

Generic name

Trilostane

Brand names

VETORYL® CAPSULES, TRILOSTANE, X, AX Pharmaceutical Corp

Manufacturer

Multiple FDA labelers

Species

Dog

Dosage forms

Capsule

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

VETORYL® CAPSULES TRILOSTANE X AX Pharmaceutical Corp Vetoryl

Dosage forms

Capsule

Indications / Uses

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.

Administration / How To Give

Oral

Storage

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Warnings / Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Side Effects

Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.

FAQ

Dog

Yes. Roxee shows this as prescription-only.

Capsule

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Related Medications

Related Conditions

Hyperadrenocorticism (Cushing’s) Cushing’s Disease (Hyperadrenocorticism) Cushing’s Disease (Hyperadrenocorticism)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: /static/meds/images/trilostane.jpg
Last refreshed: Aug 6, 2026, 7:47 p.m.
Last verified: Feb 12, 2026, 7:40 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches
Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors
Elevated total bilirubin (1 reports)
Elevated serum alkaline phosphatase (1 reports)
Ear infection NOS (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Trilostane; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-013316

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 20 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-013316

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-013316

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Elevated total bilirubin (1 reports), Elevated serum alkaline phosphatase (1 reports), Ear infection NOS (1 reports), Drug prescribing error (1 reports), Dilated renal pelvis (1 reports)

Body systems represented Signal grouping

Digestive (4), Behavior (1), Other (27)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (26 reports), Cat (6 reports)

Breed metadata in reports Metadata only

['Terrier (unspecified)', 'Dog (unknown)'] (2), Dachshund - Miniature (1), ['Chihuahua', 'Dog (unknown)'] (1), Bulldog - French (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Trilostane fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches, Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors, Elevated total bilirubin, Elevated serum alkaline phosphatase, Ear infection NOS

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Trilostane brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2026-US-013316 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
FOI · document · documents
Labeling · document · documents
SPL · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 7:40 PM UTC

Sources:

FDA application profile · official_label
Medication usage source · fda_animal_drugs
openFDA case USA-USFDACVM-2026-US-013316 · adverse_reaction
FOI · document
FOI · document

Safety & side effects

Side effects to monitor:

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches
Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors
Elevated total bilirubin
Elevated serum alkaline phosphatase
Ear infection NOS

Most reported reactions:

Elevated total bilirubin (1 reports)
Elevated serum alkaline phosphatase (1 reports)
Ear infection NOS (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Dog

Indication / use

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

Form / route / dose

Form: Capsule
Route: Oral
Confirm product label and patient-specific plan.

Warnings

High: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing …

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

VETORYL N141291C0048.pdf Official label / PI
VETORYL® CAPSULES SPL
Trilostane SPL SPL

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Dog

Manufacturer: Multiple FDA labelers

Form: Capsule

Identifiers:

NADA: 141291 NDC Package: 17033-105-30 NDC Package: 17033-110-30 NDC Package: 17033-111-30 NDC Package: 17033-112-30 NDC Package: 17033-130-30 NDC Package: 17033-160-30 NDC Package: 58597-7038-6 NDC Package: 62157-361-01 NDC Package: 62157-401-01 NDC Package: 62157-556-01 NDC Package: 62157-557-01 NDC Package: 62157-560-01 NDC Package: 62157-596-01 NDC Package: 62157-927-01 NDC Package: 62991-2736-1 NDC Package: 62991-2736-2 NDC Package: 62991-2736-3 NDC Package: 62991-2736-4 NDC Package: 62991-2736-5

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141291 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

High: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Selected filters

Reaction: Abnormal adrenocorticotropic hormone (ACTH) stimulation test Clear Body system: Digestive Clear

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Hyperglycaemia (4) Diarrhoea (3) Vomiting (3) Abnormal adrenocorticotropic hormone (ACTH) stimulation test (2) Other (24) Digestive (8) Neurologic (4) Behavior (2)

No stored openFDA reports match the selected filters. openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (4) · Loss of appetite, Diarrhea, Decreased appetite Behavior (1) · Behavioral disorder (unspecified) Other (27) · Elevated total bilirubin, Elevated serum alkaline phosphatase, Elevated blood urea nitrogen

Most Reported Reactions

Body system	Cases	Species	Serious cases
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1

Species coverage: Dog (26) Cat (6)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Digestive	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Behavior	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2026-US-013316

Storage & Handling

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

VETORYL N141291C0048.pdf Official label / PI · Labeling VETORYL® CAPSULES SPL · SPL Trilostane SPL SPL · Structured Product Label

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

SPL

FOI

VETORYL N141291C0048.pdf

Official label / PI · Labeling

Open original

VETORYL® CAPSULES

SPL · SPL

Open original

FDA Structured Product Label

VETORYL® CAPSULES

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Dechra Veterinary Products LLC
NADA: 141-291
Status: RX
Form: Capsule
Route: Oral
Species: Dog

Composition / specifications

Each capsule contains 5, 10, 20, 30, 60, or 120 mg trilostane.

Dogs

FOI · FOI

Open original

UCM508381.pdf

FOI · FOI

Open original

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/856 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/855 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/914 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2017/VETORYL%C2%AE%20CAPSULES · document · SPL
https://www.accessdata.fda.gov/spl/data/bd827b0b-7a67-4b30-936e-063c7c7a9d4f/bd827b0b-7a67-4b30-936e-063c7c7a9d4f.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/e7596834-ad63-4e37-b1f4-390fdff15fa4/e7596834-ad63-4e37-b1f4-390fdff15fa4.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/45b40fc8-9e1a-4c47-b1a9-ffabfc9f5f04/45b40fc8-9e1a-4c47-b1a9-ffabfc9f5f04.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/d23b1adb-887c-414d-8417-7886d94278d3/d23b1adb-887c-414d-8417-7886d94278d3.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/6409a33f-ec4a-422b-a0e0-1d06a9f09149/6409a33f-ec4a-422b-a0e0-1d06a9f09149.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/f8485369-2c18-475e-bc41-f00a19b89a8e/f8485369-2c18-475e-bc41-f00a19b89a8e.xml · document · Structured Product Label

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: AX Pharmaceutical Corp TRILOSTANE Trilostane Vetoryl X

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Dog • FDA-labeled species: Dog

Rx/OTC: RX

Form/route: Capsule • Oral

Applications: NADA 141-291

NDC: Packages 17033-105-30 17033-110-30 17033-111-30 17033-112-30 17033-130-30 17033-160-30 • Products 17033 58597 62157 62991 63732 69182

Documents: 3 (FOI: 2) • SPL: 1 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 81 • Cat 6 • View

Case summaries: 27 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Hyperadrenocorticism (Cushing’s) Cushing’s Disease (Hyperadrenocorticism) Cushing’s Disease (Hyperadrenocorticism)

Linked using: Fda_Label (0.95), Usage_Inferred (0.78), Usage_Inferred (0.78)

Diagnosis Codes

ICD10_CM: E24.9

Cushing syndrome, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors. (Contraindication, High)

Top reaction signals

Elevated total bilirubin (1) Elevated serum alkaline phosphatase (1) Ear infection NOS (1) Drug prescribing error (1) Dilated renal pelvis (1) Difficulty to rise (1) Diabetes mellitus (1) Dermal mass (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
17033-105-30	17033	-
17033-110-30	17033	-
17033-111-30	17033	-
17033-112-30	17033	-
17033-130-30	17033	-
17033-160-30	17033	-
58597-7038-6	58597	-
62157-361-01	62157	-
62157-401-01	62157	-
62157-556-01	62157	-
62157-557-01	62157	-
62157-560-01	62157	-
62157-596-01	62157	-
62157-927-01	62157	-
62991-2736-1	62991	-
62991-2736-2	62991	-
62991-2736-3	62991	-
62991-2736-4	62991	-
62991-2736-5	62991	-
63732-2018-4	63732	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
TRILOSTANE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Vetoryl SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
X SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
X SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
TRILOSTANE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
VETORYL N141291C0048.pdf • Official label • Official • July 14, 2026
FDA official labeling for application 141291
UCM508381.pdf • FOI summary • Official • July 14, 2026
FDA FOI summary for application 141291
UCM173123.pdf • FOI summary • Official • July 14, 2026
FDA FOI summary for application 141291

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 137 Clinical 7 Manufacturer 0 Marketing 0

Current Field Facts

overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-04-12)
overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-04-11)
overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-02-12)
side_effects: Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed. (Clinical, 2026-04-11)
storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-04-12)
storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-04-11)
storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-02-12)
contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-04-12)
contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-04-11)
contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-02-12)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-08-06)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-08-05)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-08-04)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-08-03)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-08-02)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-08-01)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-07-31)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-07-30)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-07-29)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-07-28)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
VETORYL® CAPSULES RX Trilostane Capsule • Oral Label highlights Official documents	Dechra Veterinary Products LLC	NADA 141-291	Approved	Jul 14, 2026

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog

Composition / specifications

Each capsule contains 5, 10, 20, 30, 60, or 120 mg trilostane.

Dogs

Indication

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

Dosage

The starting dose for the treatment of hyperadrenocorticism in dogs is 1.0 to 3.0 mg/lb (2.2 to 6.7 mg/kg) once a day based on body weight and capsule size. Capsules should be administered with food.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Side Effects

Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog Appetite loss (1) • Dog

Showing top 5 for Digestive.

Behavior

Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other

Elevated total bilirubin (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Dog Ear infection NOS (1) • Dog

Show more (22)

Drug prescribing error (1) • Cat Dilated renal pelvis (1) • Cat Difficulty to rise (1) • Dog Diabetes mellitus (1) • Dog Dermal mass (1) • Dog Dermal cyst (1) • Dog Dehydration (1) • Dog Death by euthanasia (1) • Dog Death (1) • Dog Collapse NOS (1) • Dog Cataract (1) • Dog Blood in urine (1) • Dog Barking (1) • Dog Azotaemia (1) • Cat Anisocoria (1) • Cat Adrenal gland disorder NOS (1) • Dog Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal movement NOS (1) • Dog Abnormal adrenocorticotropic hormone (ACTH) stimulation test (1) • Dog Abdominal mass (1) • Dog Abdominal discomfort (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Dachshund - Miniature, Male, 14 year, 5.897 kilogram • Drug: MSK, Unassigned, Oral, Frequency: 12 per hour • Reactions: Seizure NOS, Obtunded, Twitching, Restlessness, Walking difficulty… • Outcome: Euthanized

Report ID: USA-USFDACVM-2026-US-013212
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 14.00 Year
Weight: 5.897 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Unassigned
Frequency: 12 per hour

Reactions Reported:

Seizure NOS Obtunded Twitching Restlessness Walking difficulty Proprioception deficit Death by euthanasia

Outcomes: Euthanized

Dog, ['Chihuahua', 'Dog (unknown)'], Male, 14 year, 5.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 24 per hour • Reactions: Vomiting, Diarrhea • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014719
Serious AE: No
Treated For AE: No
Sex: Male
Age: 14.00 Year
Weight: 5.100 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 10 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Vomiting Diarrhea

Outcomes: Outcome Unknown

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 11 year, 7.5 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 24 per hour • Reactions: Elevated serum alkaline phosphatase, Elevated alanine aminotransferase • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014715
Serious AE: No
Treated For AE: No
Sex: Male
Age: 11.00 Year
Weight: 7.500 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 20 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Elevated serum alkaline phosphatase Elevated alanine aminotransferase

Outcomes: Outcome Unknown

Dog, Bulldog - French, Female, 7 year, 12.3 kilogram • Drug: MSK, Capsule, Oral, Dose: 30 Milligram per animal, Frequency: 24 per hour • Reactions: Skin lesion NOS, Skin hyperaemia, Folliculitis, Skin ulcer, Lack of efficacy (bacteria) - NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014532
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 7.00 Year
Weight: 12.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 30 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Skin lesion NOS Skin hyperaemia Folliculitis Skin ulcer Lack of efficacy (bacteria) - NOS

Outcomes: Ongoing

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Female, 12 year, 4.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 12 per hour • Reactions: Diarrhea, Weight gain, Hair change, Behavioral disorder (unspecified) • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014531
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 12.00 Year
Weight: 4.100 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 10 Milligram per animal
Frequency: 12 per hour

Reactions Reported:

Diarrhea Weight gain Hair change Behavioral disorder (unspecified)

Outcomes: Outcome Unknown

Dog, ['Dog (other)', 'Dog (unknown)'], Male, 13 year, 7.3 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 12 per hour • Reactions: Liver failure, Death • Outcome: Died

Report ID: USA-USFDACVM-2026-US-014530
Serious AE: Yes
Treated For AE: No
Sex: Male
Age: 13.00 Year
Weight: 7.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 20 Milligram per animal
Frequency: 12 per hour

Reactions Reported:

Liver failure Death

Outcomes: Died

Dog, ['Beagle', 'Dog (unknown)'], Male, 12 year, 19.3 kilogram • Drug: MSK, Capsule, Oral, Dose: 60 Milligram per animal, Frequency: 24 per hour • Reactions: Adrenal gland disorder NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014529
Serious AE: No
Treated For AE: No
Sex: Male
Age: 12.00 Year
Weight: 19.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 60 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Adrenal gland disorder NOS

Outcomes: Outcome Unknown

Dog, Terrier - Yorkshire, Male, 10 year, 3.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 24 per hour • Reactions: High sodium-potassium ratio, Wart, Dermal cyst, Low sodium-potassium ratio, Hyperkalaemia… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014524
Serious AE: No
Treated For AE: No
Sex: Male
Age: 10.00 Year
Weight: 3.100 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 5 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

High sodium-potassium ratio Wart Dermal cyst Low sodium-potassium ratio Hyperkalaemia Haemolysis NOS

Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluids and corticosteroids is required.

Storage & Handling

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Trilostane

Data freshness

Trilostane

Medication Snapshot

Trilostane

Indications / Uses

Administration / How To Give

Storage

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

How should this be stored?

Related Medications

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

Grouped by Body System

Most Reported Reactions

Storage & Handling

Source Documents

Owner handouts

Official label / PI

SPL

FOI

VETORYL N141291C0048.pdf

VETORYL® CAPSULES

VETORYL® CAPSULES

Dogs

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

TRILOSTANE SPL

Vetoryl SPL

Trilostane SPL

X SPL

AX Pharmaceutical Corp SPL

Trilostane SPL

AX Pharmaceutical Corp SPL

AX Pharmaceutical Corp SPL

AX Pharmaceutical Corp SPL

X SPL

TRILOSTANE SPL

Trilostane SPL

UCM173123.pdf

UCM508381.pdf

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Change Log

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)

VETORYL® CAPSULES • Capsule • Oral

Usage

Contraindications

Side Effects